INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in men and continues to be one of leading causes of male cancer-related death among the elderly. PCa has high metastatic capacity and extensively metastasizes to bone, lymph nodes, and visceral organs, such as the liver and lungs. Research over the last few decades on metastasis has revealed detailed steps of this mechanistic cascade (1): some primary tumor cells detach and escape from the original tumor sites, intravasate into circulation, extravasate out into the secondary tissues in which they begin to proliferate (2) .
Chemotaxis plays an important role in the metastasis of cancer cells, directing the motility of metastatic cells through gradients of growth factors or chemoattractants.
Osteopontin (OPN), also called secreted phosphoprotein 1 (SPP1), is a glycophosphoprotein cytokine that is expressed by numerous cells and secreted into body fluids. This extracellular matrix protein is an active player in many physiological and pathological processes including bone mineralization, defense against infectious agents, blood vessel formation, arteriosclerosis, disruption of the growth of calcium oxalate crystals and nitric oxide production, and tumorigenesis (3, 4) .
Substantial evidence associates OPN expression with tumor invasion and metastasis (5) in a number of cancers such as breast (6) , prostate (7) , lung (8) , stomach (9) colon (10), brain (11) and other cancers (12) .
Transcriptional regulation of OPN is complex and involves multiple signal transductions (13) .
Identifying transcriptional regulators that contribute to the modulation of OPN expression is of interest for therapy that aims to control the OPN-mediated metastatic phenotype. Several known cis-acting transcription factors have been described and most of them have been localized to a conserved region at 250 bp upstream of the proximal promoter. Potential binding sites for transcriptional regulators, such as AP-1, Myc, Oct-1, USF, v-Src, TGF-b/BMPs/Smad/Hox, Wnt/βcatenin/APC/GSK-3b/Tcf-4, Ras/RRF, TF53, Runx2 and ETS family members, have been identified (14) (15) (16) (17) (18) (19) (20) (21) .
In the past few years, the ERG (ETS-related gene) gene, a member of the ETS transcriptional factor family, has been shown to be highly overexpressed in most PCa (60 to 80% according to the studies) (22, 23) . Thus, its presence in prostate cells perturbs normal gene expression. ERG overexpression (and to a lesser extent the overexpression of some other ETS family members) is the result of chromosomal translocations between the androgen-regulated Trans-membrane protease serine 2 (TMPRSS2) gene promoter and the coding sequence of the ERG gene (24) . The TMPRSS2:ERG fusion is associated with aggressiveness and recurrence of PCa (25) , metastasis (26) and PCa-specific death (27, 28) .
Two members of the ETS family, PEA3 and Ets-1, have been demonstrated to be partially responsible for the overexpression of OPN in human breast cancer and in murine colorectal cancer cells, respectively (29, 30) . In this study, we investigated whether ERG overexpression stimulates OPN expression in PCa cells. OPN promoter-luciferase deletion constructs in transient transfection experiments demonstrate OPN transactivation by the ERG factor. After localizing ETS binding site(s) (EBS) in sequences conserved across several species, we characterized the OPN promoter-ERG transcription factor complex using an electromobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP). Due to the expression of the TMPRSS:ERG fusion gene in prostate tumor cells, the overexpression of ERG in prostate cancer cells increased OPN expression. The coincident expression and colocalization of TMPRSS2:ERG and OPN in primary prostate tumor tissue samples suggest that ERG may be implicated in the dysregulation of OPN in prostate cancer.
MATERIALS AND METHODS
Patient information and tissue selection-All prostate cancer patients included in this study had undergone radical prostatectomy in the Lille University Hospitals. Clinical data and patient consent were provided by the referring physician. Immunohistochemical studies were conducted on formalin-fixed and paraffin-embedded prostate specimens. Frozen tissues used for RT-PCR involved primary tumors from 35 male patients (mean age: 63 years, with Gleason score >5) and were obtained EMSA and supershift assays-The assays were performed as described in ref. (33) using purified ERG protein (expressed and purified using the T7-Impact™ System (New England Biolabs®) as described previously (34) ) and ERG transfected-HeLa nuclear extracts. An oligonucleotide (Eurogentec) probe nt -123 to -101 (5'-CCAGAGGAGGAAGTGTAGGAGCAGGT) was prepared by end-labeling double-stranded oligonucleotides with [ 32 P]ATP (2500 Ci/mmol) using T4 polynucleotide kinase (Promega) followed by G-50 column purification (GE-Healthcare).
Radiolabeled oligonucleotide probes (100,000 cpm) were incubated with protein or nuclear extracts in a total volume of 20 µl for 30 min at 20°C. Binding buffer consisted of 100 ng/ml of poly(dI-dC)-poly(dI-dC), 20 mM Tris HCl (pH 7.9), 50 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 0.02% NP-40 and 10% glycerol. DNA-protein complexes were resolved by electrophoresis for 1 h at 200 V on a 5% non-denaturing polyacrylamide gel. The gels were dried, and signals were detected by exposure to autoradiography film. Nuclear extract was used as the negative control. In competitive binding assays, unlabeled oligonucleotides were added in 100 M excess. Chromatin immunoprecipitation (ChIP)-ChIP assays were performed as previously described (35) by using anti-ERG (sc-353, Santa Cruz Biotechnology). Briefly, formaldehyde crosslinked chromatin was sonicated and immunoprecipitated with either IgG (control) or the indicated Ab.
ChIP analyses were performed in at least triplicate using distinct DNA preparations.
Immunoprecipitated DNA was purified and quantified by PCR. The targeted OPN promoter sequence (-269;-75) was amplified using the following primers: 5'-CATGGGATCCCTAAGTGCTC-3', 5'-TGAGGTTTTCTGCCACTGCCC-3'. The target irrelevant sequence was amplified using primers: a:
5'-TGAGAGCAATGAGCATTCCGATG-3' and B: 5'-CAGGGAGTTTCCATGAAGCCAC-3'.
RNA preparation and RT-PCR-Total RNA was extracted using the Nucleospin RNA II kit according to the manufacturer's protocol (Macherey-Nagel). One microgram of total RNA was reverse-transcribed using Superscript II RT (Invitrogen), random hexamers (Roche), and dNTPs at 42°C for 1 h. OPN fragments were then amplified using the High Fidelity PCR Master kit (Roche) and the appropriate oligonucleotides (A: 5'-TGAGAGCAATGAGCATTCCGATG-3', B: 5'-CAGGGAGTTTCCATGAAGCCAC-3') using the following cycling parameters: initial denaturation at 94°C (5 min), then 30 cycles of 94°C (30 s), annealing at 60°C (30 s) and extension at 72°C (30 s), followed by a final extension at 72°C (7 min). The TMPRSS2-ERG fusion transcripts were amplified with the primers: TMPRSS2 forward primer 5'-CGCGAGCTAAGCAGGAGGC-3' and ERG reverse primer 5'-GTAGGCACACTCAAACAACGACTGG-3' described in (24) . As an internal control, hypoxanthine-guanine phosphoribosyltransferase (HPRT) fragments were also amplified under the 6 same conditions (forward primer: 5'-GCTGGTGAAAAGGACCTCT-3' and reverse primer: 5'-AAGTAGATGGCCACAGGACT-3'). PCR products were analyzed by electrophoresis in a 2% agarose gel.
Cellular extract preparation and Western blot analysisCellular extract preparation
and Western blot analysis were carried out as previously described (35, 36 Fig. S1 ). This analysis shows that the OPN proximal promoter is well-conserved in all species analyzed, and two domains were defined: one from nt -289 bp to +6 bp, the other from nt -1100 kb to -920 kb. These two conserved domains were scanned using Transfac to find potential EBS composed of the 5' consensus sequence -GGA/W-3' (W:A or T). We found only one putative analysis) also disclosed Runx2, SBF-1, C/EBP and AP-1 sites, which have already been reported (30) .
To test ERG transactivation, a series of sequential 5'-deletion mutant constructs were prepared from the region of the promoter sequence that confers efficient transcription of the OPN gene (37).
The 5'-deletion sequences were cloned into the pGL3 reporter plasmid (Fig. 1A) and assayed for ERG responsiveness via luciferase activity in transient transfected HeLa cells (Fig. 1B) Interaction of ERG with the OPN promoter-To investigate whether these EBS were direct ERG targets, we performed an electromobility shift assay (EMSA) using a Identification of a functional cis-regulatory element-To further characterize which EBS are involved in ERG binding within the WT nt -126 to -101 oligonucleotide region, we used site-directed mutant probes and constructs ( Fig. 3A) and analyzed them using EMSA ( Fig. 3B and 3C ) and luciferase-promoter assays (Fig. 3D) . A gel-shift complex (S) was present with the wt probe itself and the mutant 2 probe, but not with the mutant 1 or mutant 1+2 probes (Fig. 3B) . In contrast, this complex was absent in 100-fold excess of unlabeled wt and mutant 2 probes, but persisted with mutant 1 probe (Fig. 3C) . Similar patterns were obtained with nuclear extracts of transfected HeLa cells (data not shown).
Next, to assess the functionality of the EBS, we investigated the effect of ERG overexpression using a luciferase reporter construct driven by mutated EBS. The OPN promoter fragment -136/+77, with ERG-responsive transcriptional activity similar to the intact 1518 bp promoter (Fig. 1B) , was used as a template to introduce site-directed mutations in predicted EBS1 and EBS2 sequences, named OPN -136/+77 mutant1 and OPN -136/+77 mutant2, respectively, and transfected into HeLa cells (Fig. 3D) . A mutation in nt -119 to -115 from GGAGGAAG to GGTAAAAG resulted in the suppression of ERG transactivation. In contrast, luciferase activity was not affected by mutations in nt -112 to -106 from GTAGGAG to GTCGGAG. Thus, these experiments suggest that ERG may play a direct role in OPN promoter activation through a very specific EBS located at nt -118 to -115.
Up-regulation of endogenous OPN expression in prostate cancer cells with stable expression of ERG and TMPRSS2:ERG-A high incidence recurrent fusion of TMPRSS2 with ERG
has recently been highlighted in prostate cancer. This fusion results in aberrant androgen-regulated ERG in prostate cells. We therefore examined endogenous OPN expression in a prostate cell line, PC3c, that we stably transfected with ERG and TMPRSS2:ERG (Fig. 4) . Efficiencies of ERG and TMPRSS2:ERG overexpression were characterized in several subclones and compared with nontransfected cells and empty pcDNA3 vector-transfected cells by RT-PCR (Fig. 4A ) and Western blotting (Fig. 4B) . The molecular weight of ERG was expected to be 55 kD whereas TMPRSS2:ERG was expected to be 49 kD, consistent with the deletion of 32 amino acids from the N-terminus (Fig.   4B ). Results obtained with representative subclones were similar for several subclones (data not shown). Expression analysis showed that, compared to the non-transfected PC3c and empty pcDNA3 vector-transfected PC3c, OPN expression was greater in clones that overexpress ERG following transfection of ERG and TMPRSS2:ERG. Interestingly, ChIP assays revealed that ERG transcriptional factors were associated with the OPN promoter in clones of PC3c cells expressing ERG and TMPRSS2:ERG in which OPN was up-regulated but not in empty pcDNA3 clones (Fig. 4C) .
Together, these data suggest that ERG and TMPRSS2:ERG gene fusion products bind to the cisregulatory domain of the endogenous OPN promoter in PC3c cells and transactivate this gene.
TMPRSS2:ERG status and osteopontin/TMPRSS2:ERG expression in human primary
prostate cancers-Samples of human primary prostate cancers were assessed for OPN and TMPRSS2:ERG transcript expression using RT-PCR on total isolated RNA (Table 1A) (38, 39) . Among these TMPRSS2:ERG+ tumors, 96% were also positive for OPN expression. Using a twotailed, cross-tabulated Fisher's exact test showed a significant association (P <0.01) between TMPRSS2:ERG and OPN expression (Table 1B) .
Next, we examined the expression of ERG and OPN from human prostate tumors (Fig. 5A ).
Using immunohistochemistry, we observed the co-expression of ERG and OPN in areas of prostatic adenocarcinoma. Staining against ERG was nuclear with a moderate to strong signal in adenocarcinomatous glands as shown in Fig. 5 . Osteopontin was detected in the cytoplasm of adenocarcinomatous glands. As a control, in normal prostatic glands, we did not observe ERG expression except in endothelial cells of vessels (Supplementary Figure S4) , whereas, as previously described (51) Spearman's correlation coefficient was used to evaluate the correlation between protein expression levels (refered as % of cells stained) of ERG and OPN in IHC (Fig. 5B) . Our data showed that there was a significantly positive correlation between expression levels of ERG and OPN (r= 0.531; P < 0.05).
DISCUSSION
OPN is a secreted phosphoprotein that has been found to facilitate anchorage of normal bone or cancer cells to mineralize tissue surfaces (40) . This protein can be considered as one of the critical determinants in bone formation and tumor progression. The malignant and metastatic phenotype of human cancers has been correlated with elevated OPN expression, both at mRNA and protein levels 
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